ITI-007: Phase Ib/II data

A double-blind, placebo-controlled, multiple-ascending dose Phase Ib/II trial in 45 patients showed that oral ITI-007 at doses of up to 140 mg/day for 5 days was well tolerated with no extrapyramidal ...